Institut de Pharmacologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique (CNRS), Université de Nice Sophia Antipolis, 660 Route des Lucioles, 06560 Valbonne, France.
Neuropharmacology. 2010 Jun;58(7):987-1001. doi: 10.1016/j.neuropharm.2010.01.001. Epub 2010 Jan 11.
Although stroke remains a leading cause of death and adult disability, numerous recent failures in clinical stroke trials have led to some pessimism in the field. Interestingly, NeuroAid (MLC601), a traditional medicine, particularly used in China, South East Asia and Middle East has been reported to have beneficial effects in patients, particularly in post-stroke complications. Here, we demonstrate in a rodent model of focal ischemia that NeuroAid II (MLC901) pre- and post-treatments up to 3 h after stroke improve survival, protect the brain from the ischemic injury and drastically decrease functional deficits. MLC601 and MLC901 also prevent neuronal death in an in vitro model of excitotoxicity using primary cultures of cortical neurons exposed to glutamate. In addition, MLC601/MLC901 treatments were shown to induce neurogenesis in rodent and human cells, promote cell proliferation as well as neurite outgrowth and stimulate the development of a dense axonal and dendritic network. MLC601 and MLC901 clearly represent a very interesting strategy for stroke treatment at different stages of the disease.
尽管中风仍然是导致死亡和成年人残疾的主要原因，但最近临床中风试验的多次失败导致该领域出现了一些悲观情绪。有趣的是，NeuroAid（MLC601）是一种传统药物，特别是在中国、东南亚和中东地区使用，据报道对中风患者有有益的影响，特别是对中风后的并发症。在这里，我们在局灶性缺血的啮齿动物模型中证明，NeuroAid II（MLC901）在中风后 3 小时内进行的预处理和后处理可提高存活率，保护大脑免受缺血性损伤，并显著降低功能缺陷。MLC601 和 MLC901 还可以在体外使用皮质神经元原代培养物暴露于谷氨酸的兴奋性毒性模型中预防神经元死亡。此外，MLC601/MLC901 处理还显示出在啮齿动物和人类细胞中诱导神经发生，促进细胞增殖以及神经突生长，并刺激密集的轴突和树突网络的发育。MLC601 和 MLC901 显然代表了一种非常有趣的中风治疗策略，可以在疾病的不同阶段使用。
